Real-world efficacy and safety of anti-CGRP drugs in drug-resistant chronic migraine

Key clinical point: This real-world analysis confirms the benefits of anticalcitonin gene-related peptide (anti-CGRP) drugs, erenumab, galcanezumab, and fremanezumab, in drug-resistant chronic migraine; however, intensified erenumab regimen showed limited benefits.

Major finding: At week 12, all patients treated with erenumab (P < .001), galcanezumab (P < .001), or fremanezumab (P = .028) achieved a significant reduction in mean monthly migraine headache days, with treatment-associated toxicity being higher with erenumab vs galcanezumab and fremanezumab (P  =  .04). An intensified erenumab regimen demonstrated similar efficacy but with more severe grade 3/4 toxicity (140 vs 70 mg: 14.8% vs 0%; P  =  .038).

Study details: This was a retrospective study including 104 patients with drug-resistant chronic migraine who had failed >3 conventional migraine preventive treatments and received erenumab, galcanezumab, or fremanezumab.

,

Disclosures: This study did not receive any financial support. The authors declared no conflicts of interest.

Source: Cantarelli L et al. Efficacy and safety of erenumab, galcanezumab, and fremanezumab in the treatment of drug-resistant chronic migraine: Experience in real clinical practice. Ann Pharmacother. 2022 (Aug 18). Doi: 10.1177/10600280221118402